Nabriva Therapeutics plc
NBRV evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NBRV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Market Cap
—
Cash Runway
—
Lead Asset
contepo (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2023.
Tracking 3 pipeline candidates for Nabriva Therapeutics plc.
Run Nabriva Therapeutics plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Nabriva Therapeutics plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
Profitable (positive operating cash flow)
OCF $511K · Net income -$12M
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is Nabriva Therapeutics plc's lead drug candidate?
Nabriva Therapeutics plc's most advanced tracked candidate is contepo (Preclinical) for cUTIs, including AP.
Who is the CEO of Nabriva Therapeutics plc?
Colin Broom, MD is the chief executive officer of Nabriva Therapeutics plc (NBRV).
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.